There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis – increasing the risk of bleeding – or less intensive therapy – reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death. Prolocor’s precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.
Location: United States, Pennsylvania, Philadelphia
Employees: 1-10
Total raised: $6.9M
Founded date: 2020
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.03.2024 | - | $1.7M | - |
| 18.08.2022 | Seed | $5.2M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 01.03.2024 | Prolocor Raises $1.7M in Bridge Funding | Prolocor, a Philadelphia, PA-based healthcare startup developing a precision diagnostic test, raised... | finsmes.co... |
| 18.08.2022 | Prolocor Raises Combined $5.2M in Seed Round and NIH SBIR Gr... | Prolocor, a Philadelphia, PA-based healthcare startup, raised $5.2M in seed and grant funding. The r... | finsmes.co... |